ASE · Biotechnology

AIM (AIM) Stock

$0.24 -5.84% ASE: AIM Healthcare

Valuation

MetricValue
Price$0.24
Market Cap$801193
P/E Ratio-0.09
P/B Ratio0.57
P/S Ratio10.14
EPS (TTM)$-8.62
52-Week High$19.74
52-Week Low$0.21
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE261.84%
ROA-154.64%
ROCE-417.58%
Gross Margin-1.79%
Operating Margin-103.70%
Net Margin-141.23%
Debt/Equity2.15
Current Ratio0.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-20.0M$-32.0M$-20.0M$-11.0M
Net Profit$-19.0M$-19.0M$-29.0M$-17.0M$-14.0M
EPS$-14.67$-14.69$-21.64$-11.22$-8.62
Op Margin-13954.1%-14129.6%-15800.0%-11630.6%-11961.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$58.0M$40.0M$19.0M$9.0M$6.0M
Total Liabilities$1.0M$2.0M$9.0M$10.0M$16.0M
Cash$32.0M$27.0M$5.0M$2.0M$1.0M
Borrowings$0$1.0M$1.0M$3.0M$5.0M

Latest News

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program GlobeNewswire · Jul 7, 2026 AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones GlobeNewswire · Jun 24, 2026 AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series GlobeNewswire · Jun 22, 2026 AIM ImmunoTech Trial of Ampligen With AstraZeneca's Imfinzi to Treat Pancreatic Cancers Doses Last Patient MT Newswires · Jun 18, 2026 AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer GlobeNewswire · Jun 18, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-16.0M$-21.0M$-15.0M$-11.0M
Investing Cash Flow$-1.0M$11.0M$-1.0M$5.0M$1.0M
Financing Cash Flow$0$0$0$3.0M$0
Net Cash Flow$-6.0M$-5.0M$-22.0M$-4.0M$1.0M
Free Cash Flow$-15.0M$-16.0M$-22.0M$-15.0M$-11.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.02
FCF Yield-1224.78%
Quick Ratio1.01
Interest Coverage-10.27
Return 1Y-96.97%
Return 3Y-99.55%
Return 5Y-99.87%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CANFCan-Fite BioPharma Ltd. $3.30 -2.37% -0.74 $1.78M 0.00%
ENSCEnsysce Biosciences, Inc. $0.26 -1.95% -0.08 $2.38M 0.00%
KALA $0.76 +3.59% -0.76 $14.62M 0.00%
KTTA $0.45 -2.17% -0.25 $3.35M 0.00%
OGEN $0.50 -1.96% -0.14 $2.26M 0.00%

About AIM

AIM is led by CEO Thomas K. Equels, employs 21 people, headquartered in US, publicly traded since 1995.

AIM stock trades at $0.24 with a market capitalization of $801193. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of 0.57, price-to-sales of 10.14. Over the past 52 weeks the stock has ranged between $0.21 and $19.74, and currently trades 98.8% below its 52-week high.

On profitability, AIM generates a return on equity (ROE) of 261.84% — well above the market average, a sign of a high-quality business, return on capital employed of -417.58%, an operating margin of -103.70%, a net profit margin of -141.23%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides